Know How COVID-19 Oral Antivirals Compare
You'll start to see the new COVID-19 oral antivirals, nirmatrelvir/ritonavir (Paxlovid) and molnupiravir.
Either is an option for outpatients with COVID-19 who are at high risk of developing serious illness (age 65 or older, diabetes, etc)...regardless of vaccination status.
They're started within 5 days of symptoms...and patients don't currently have to pay for these meds.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote